Second-Line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib

Frontiers in Medicine - Switzerland
doi 10.3389/fmed.2017.00036
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Frontiers Media SA

Related search

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

Korean Journal of Internal Medicine
Internal Medicine
2007English

Treatment Paradigms for Patients With Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line

Current Oncology
Oncology
2012English

On the Pharmacogenetics of Non-Small Cell Lung Cancer Treatment

Expert Opinion on Drug Metabolism and Toxicology
MedicineToxicologyPharmacology
2016English

Pharmacoeconomic Evaluation of PD-L1 Receptor Inhibitors for the Second Line Treatment of Metastatic Non-Small Cell Lung Cancer

Medical Technologies. Assessment and Choice
2018English

Clinical Studies on Conformal Radiotherapy Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Second-Line Treatment of Non-Small Cell Lung Cancer

Tropical Journal of Pharmaceutical Research
PharmacologyPharmaceutical Science
2016English

Redefining Treatment Paradigms in First-Line Advanced Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Anaplastic Lymphoma Kinase (ALK) Inhibitors for Second-Line Therapy of Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2012English

PCN37 Cost-Minimization Analysis of Second-Line Chemotherapy for Non-Small-Cell Lung Cancer (NSCLC)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Immunotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy